Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma
NCT02394210 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 415
Last updated 2021-09-14
Summary
Post-authorisation prospective follow-up study to assess the clinical impact on time to progression (TTP) from the start of anti- multiple myeloma treatment at the onset of asymptomatic relapse/biological progression versus start of treatment at the time of symptomatic relapse.
Conditions
Sponsors & Collaborators
-
Celgene
lead INDUSTRY
Principal Investigators
-
Mireya Navarro, MD · Celgene
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-14
- Primary Completion
- 2021-05-18
- Completion
- 2021-05-18
Countries
- Spain
Study Locations
More Related Trials
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT00065351 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
NCT01237249 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
NCT00691704 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318 ·Status: RECRUITING
-
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT03989414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
NCT01191060 ·Status: COMPLETED ·Phase: PHASE3
-
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT05675319 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
NCT00723359 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain
NCT02946333 ·Status: COMPLETED
-
STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
NCT02215980 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
NCT03836014 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.
NCT02797041 ·Status: UNKNOWN
-
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04975399 ·Status: TERMINATED ·Phase: PHASE1
-
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
NCT02387879 ·Status: UNKNOWN
-
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226 ·Status: COMPLETED
-
Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
NCT02692339 ·Status: COMPLETED
-
Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients
NCT02426723 ·Status: COMPLETED ·Phase: PHASE1
-
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
NCT03000634 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
NCT06659770 ·Status: NOT_YET_RECRUITING